Introduction {#s1}
============

Clathrin-mediated endocytosis is a conserved and ubiquitous process for internalizing material from the cell surface. The Adaptor Protein-2 (AP2) complex serves as a bridge between cargo at the plasma membrane and clathrin. The AP2 core complex contains binding sites for membrane phospholipids and endocytic cargo while the appendages bind clathrin and accessory proteins that coordinate endocytosis ([@bib42]). AP2 thereby binds target proteins on the surface of the cell and assembles the machinery necessary for internalization of cargo.

AP2 can adopt functionally different conformations. The first crystal structure of the core complex revealed that the binding pockets for cargo and membrane were partially occluded ([@bib5]). This structure was proposed to represent a closed, inactive conformation of AP2. Cocrystallization with cargo peptides led to partially open or fully open conformations ([@bib22]; [@bib20]). The open conformation places the cargo- and membrane-binding pockets in coplanar face of the complex and is therefore thought to be the active form of AP2. It has been difficult to determine whether AP2 reorganization is an obligatory process in vivo.

What regulates the switch from closed to open conformation? One model proposes that AP2 can open by simply binding the peptide motifs of cargo proteins and phosphatidylinositol 4,5-bisphosphate (PIP~2~) on the plasma membrane ([@bib18]; [@bib21]). Alternatively, AP2 might require association with clathrin and phosphatidylinositol-3-phosphate to bind cargo at the plasma membrane ([@bib34]). Another model suggests that the open form of AP2 is induced by phosphorylation ([@bib9]; [@bib30]; [@bib6]; [@bib36]; [@bib18]). Alternatively it is possible that the complex is activated by one of the many other clathrin-associated proteins.

The most likely of these proteins would be one that precedes AP2 at sites of endocytosis. Examples include Epidermal growth factor receptor substrate 15 (Eps15), intersectin, and most recently, Fer/CIP4 Homology domain only (FCHo) proteins (Syp1p in yeast) ([@bib39]; [@bib41]). The role of FCHo at endocytic sites is poorly defined. In *syp1* mutants, which encodes the yeast homolog of FCHo, endocytic patches are less frequent, but still progress to coated pits ([@bib35]; [@bib39]). When FCHo proteins were knocked down in tissue culture cells, AP2 failed to bind membrane ([@bib16]). However, others found that knockdown of FCHo did not prevent AP2 association with the membrane ([@bib44]) but that there is an increased tendency for endocytic events to abort ([@bib4]) with flat clathrin plaques forming rather than clathrin-coated pits ([@bib27]). These studies suggest that FCHo might regulate AP2 during the formation of a clathrin-coated pit. On the other hand, there is evidence that FCHo may be acting in a parallel endocytic pathway with ESCRT0 in *Caenorhabditis* *elegans* ([@bib26]). In fish, FCHo appears to act in BMP signaling during development ([@bib44]). Thus it is unclear whether FCHo proteins function via AP2 or in parallel to AP2 in clathrin coat assembly, or in an entirely unrelated pathway.

Here, we report that FCHo directly activates AP2 by promoting the open conformation. In FCHo mutants in the nematode *C. elegans*, AP2 is functionally inactive and endocytosis of surface cargo is reduced. However, the requirement for FCHo can be bypassed by mutations in AP2 that specifically destabilize the closed conformation of AP2. FCHo is comprised of an F-BAR domain ([@bib17]), a linker region, and a C-terminal μ-homology domain related to the medium subunit of AP2 ([@bib35]; [@bib39]; [@bib41]). The region of FCHo that is required for activation of AP2 is not the F-BAR or the μ-homology domain but rather a conserved region found in the linker called the AP2 activator domain (APA). This small domain from all metazoan orthologs of FCHo proteins, including SH3-containing GRB2-like protein 3-interacting protein 1 (SGIP1), binds AP2 and is sufficient to activate the AP2 complex in vivo in the absence of the endogenous FCHo protein. We propose that the FCHo/SGIP class of proteins evolved to promote endocytosis by binding to, and stabilizing the open conformation of AP2.

Results {#s2}
=======

FCHo is required for AP2-dependent endocytosis {#s2-1}
----------------------------------------------

Mutations in the AP2 complex alpha and mu subunits in *C. elegans* (encoded by the *apa-2* and *apm-2* genes) result in animals with pleiotropic phenotypes including reduced body length (Dpy), egg-laying defects (Egl) and uncoordinated locomotion (Unc). In addition, they exhibit a unique 'jowls' phenotype, in which the mutants exhibit bulges in the cuticle on either side of the head ([@bib14]). Deletion of the sigma subunit (*aps-2*) produces a similar 'jowls' phenotype ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), while the beta subunit is shared by both AP1 and AP2 in *C. elegans* and mutations in *apb-1* are lethal. We screened for mutants with the jowls phenotype and identified multiple mutations in three genes coding for alpha adaptin, mu2 adaptin and the nematode homolog of FCHo ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We generated a deletion allele *fcho-1(ox477)* by transposon excision ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}); all six mutant alleles of *fcho-1* produced defects strikingly similar to mutants lacking AP2 subunits, including the 'jowls' phenotype ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), suggesting that AP2 function is compromised in the absence of FCHo.10.7554/eLife.03648.003Figure 1.Loss of FCHo compromises AP2 activity.(**A**) Animals cropped to highlight jowls (red arrrowheads, anterior up) shared by *fcho-1* and AP2 subunit mutants (*apa-2*, *apm-2*, *aps-2*). (**B**) Left, representative confocal micrographs of coelomocytes in worms expressing GFP-tagged alpha subunit. Images represent maximum projections of Z-slices through ∼1/2 of a coelomocyte. Numbers indicate the coefficient of variance of pixel intensities across coelomocytes (excluding the cell periphery). \*p \< 0.01 unpaired, two-tailed t-test. Right, normalized histograms of pixel intensities (logarithmic scale). Arrow indicates higher intensity pixels that are missing in *fcho-1* mutants. (**C**) Time-lapse montages of FRAP experiments on coelomocytes expressing alpha:GFP in adult hermaphrodites. The outlined membrane region was photobleached at time = 0. (**D**) FRAP assay. Average recovery curves and time constants of fluorescence after photobleaching. \*p \< 0.01 unpaired, two-tailed t-test on data from 12 fcho(+) coelomocytes and 14 fcho(−) coelomocytes. (**E**) Cargo assay. Micrographs of intestinal cells (anterior left) expressing a GFP-tagged transmembrane cargo internalized by AP2. The cargo is a truncated CD4 transmembrane construct with a YxxΦ cargo recognition motif ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The average pixel intensity along an intestinal basal-lateral membrane in fcho(+) animals (n = 11) is 972 ± 85 arbitrary units (au) and 5610 ± 416 au in fcho(−) mutants (n = 12). p \< 0.01 unpaired, two-tailed t-test. Data in (**B**), (**D**) and (**E**) represent the mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.003](10.7554/eLife.03648.003)10.7554/eLife.03648.004Figure 1---figure supplement 1.FCHO-1 and AP2 regulate the same pathways.(**A**) Diagram of the *fcho-1* locus in *C. elegans* indicating four point mutations and two deletions associated with a loss-of-function phenotype. The targeted deletion (*ox477*) was generated by mobilizing the *Mos1* transposon and repairing the broken chromosome with a recombinant template that replaces the first eight exons with a positive selection (*unc-119* rescue). *ox477* was used exclusively throughout this study as fcho(−). (**B**) Images of animals cropped in [Figure 1A](#fig1){ref-type="fig"}. fcho(−) and AP2 subunit(−) animals are dumpy and egg-laying defective. Red arrowheads point to jowls. (**C**) Diagram of artificial GFP-CD4 AP2 cargo. GFP was flanked by two 12 amino acid flexible linkers and inserted between a secretion signal peptide from *C. elegans* PAT-3 and a modified human CD4 truncated to include two immunoglobulin domains, the transmembrane domain, and eight amino acids from the cytoplasmic domain ([@bib47]). The four amino acid YxxΦ motif from the C-terminus of the *C. elegans* lysosome-associated membrane glycoprotein, LMP-1, was appended. (**D**) Cargo assay (amount of GFP-tagged cargo on intestinal cell membrane). \*\*p \< 0.01, unpaired, two-tailed t-test compared to WT, n ≥ 9. (**E**) Brood size assay. Number of fertilized embryos produced by individual hermaphrodites of the indicated genotype. \*p \< 0.05, \*\*p \< 0.01, unpaired, two-tailed t-test compared to WT, n ≥ 8. Values for WT and *apa-2* samples were previously published ([@bib14]). (**F**) Starvation assay. Days required for a worm population to expand and consume the bacterial food. \*\*p \< 0.01, unpaired, two-tailed t-test compared to WT, n = 12. Data in (**D**), (**E**) and (**F**) represent the mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.004](10.7554/eLife.03648.004)10.7554/eLife.03648.005Figure 1---figure supplement 2.Recessive alleles isolated from genetic screen for 'jowls' phenotype \* independently identified 'jowls' mutant.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.005](10.7554/eLife.03648.005)

In *C. elegans,* the FCHO-1 protein is localized to the plasma membrane and binds to AP2 in a complex with Eps15 and intersectin ([@bib26]). To determine if FCHo is required to recruit AP2 to the plasma membrane we examined fluorescently-tagged alpha adaptin. In the wild type, AP2 is found in concentrated patches on the plasma membrane ([Figure 1B](#fig1){ref-type="fig"}). In *fcho-1* mutants, AP2 is associated with the plasma membrane ([Figure 1C](#fig1){ref-type="fig"}), but does not form clusters, consistent with previous reports ([@bib16]; [@bib4]; [@bib26]). To measure the kinetics of membrane association we performed in vivo Fluorescence Recovery After Photobleaching (FRAP) on coelomocytes. Coelomocytes are scavenger cells which exhibit high levels of endocytosis ([@bib37]). The fluorescence signal recovered approximately three times faster after bleaching in the absence of FCHo ([Figure 1C,D](#fig1){ref-type="fig"}). Thus, FCHo stabilizes patches of AP2 on the membrane and limits its mobility, consistent with previous studies ([@bib16]; [@bib4]).

To determine whether clathrin-mediated endocytosis is compromised in *fcho-1* mutants, we assayed endocytosis of a fluorescently tagged transmembrane protein. This molecule is comprised of a GFP-tagged CD4 protein with a tyrosine cargo recognition motif ([Figure1---figure supplement 1C](#fig1s1){ref-type="fig"}). Tyrosine motifs comprised of YxxΦ, where x is any amino acid, and Φ is a large hydrophobic residue, bind the mu2 subunit of AP2 and are required for AP2-mediated internalization ([@bib29]; [@bib31]). In wild-type worms, very little CD4-GFP is expressed on the surface of intestinal cells ([Figure 1E](#fig1){ref-type="fig"}). However, this cargo accumulates on the cell surface in mutants lacking AP2 subunits and in *fcho-1* mutants, suggesting that AP2-dependent endocytosis is defective in *fcho-1* mutants ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). In addition the phenotype is not enhanced in double mutants indicating that FCHO-1 acts in the same pathway as AP2.

Mutations in AP2 bypass the requirement for FCHo {#s2-2}
------------------------------------------------

To identify components downstream of FCHo, we performed a genetic screen for mutations that suppress a null mutation in *fcho-1*. To increase the probability of getting missense mutations we used the mutagen *N*-ethyl-*N*-nitrosourea (ENU), which can generate transversions and can therefore swap charges, or hydrophilic and hydrophobic amino acids. In addition, we designed a multigenerational screen to select for subtle improvements in fitness. Wild-type animals grow rapidly and starve a culture plate in 5 days, whereas *fcho-1* mutants exhibit reduced fecundity ([Figure1---figure supplement 1E](#fig1s1){ref-type="fig"}) and require twice as long to consume the same amount of food ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). We selected for suppressors that rapidly starved plates, and identified 71 dominant mutations that confer increased fitness to *fcho-1* mutants and suppressed the jowls phenotype. All of these suppressed strains contained second site missense mutations in one of the four subunits of AP2 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) and none exhibited loss-of-function phenotypes for these adaptin genes ([Figure 2---figure supplement 1A--C](#fig2s1){ref-type="fig"}). These mutations all occur at conserved amino acids, and cluster at sites likely to stabilize the closed (inactive) conformation when placed on the crystal structures of AP2 ([Figure 2A--C](#fig2){ref-type="fig"}) ([@bib5]; [@bib22]; [@bib20]). These mutations can be classified into four groups: (1) residues that lie in the bowl-like interface between the mu2 subunit and the other three subunits, (2) residues that stabilize the insertion of the N-terminus of the beta subunit into the cargo binding motif of sigma, (3) residues in the alpha subunit that are found in the helical solenoid that lies across the top of the complex, and (4) the phosphorylation site on the mu2 subunit. It is likely that these mutations destabilize the closed conformation of AP2, suggesting that the open conformation of AP2 may bypass the requirement for FCHo. In other words, these mutations would promote an open conformation of AP2, suggesting that AP2 may dwell in the closed state in the absence of FCHo.10.7554/eLife.03648.006Figure 2.Mutations in AP2 closed conformation interfaces suppress fcho(−).Predicted location of the mutated worm residues within the inactive (PBD ID: 2VGL) and active (PBD ID: 2XA7) crystal structures of the vertebrate AP2 core complex. Alpha is blue, beta is green, mu2 is pink, and sigma2 is cyan. The residue numbers are from the worm subunits and parentheses indicate the corresponding vertebrate residue. \* designates mutations isolated twice, and † designates mutations isolated thrice. ‡ designates mutations that were combined to re-establish a salt bridge between beta and mu (See [Figure 5](#fig5){ref-type="fig"}). (**A**) Mutations at the contact interface between the mu domain and the other three subunits. These contacts are disrupted upon opening. To visualize the contact surface in the closed conformation, the mu domain has been flipped to the right. Small renderings (left) show the closed ([@bib5]) and open conformations ([@bib20]); the plasma membrane would be below the complex in this view. The K411E mutation on the mu domain (white residue) was not isolated from the fcho-1 suppressor screen, but was engineered (See [Figure 5](#fig5){ref-type="fig"}). (**B**) Mutations in the latching mechanism formed by the N-terminus of beta and the di-leucine motif binding-pocket of sigma2. (**C**) Mutations in alpha cluster along the hinge region that flexes during opening.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.006](10.7554/eLife.03648.006)10.7554/eLife.03648.007Figure 2---figure supplement 1.Suppression of fcho-1 by missense mutations in individual AP2 subunits.For (**A**--**C**), the AP2 mutation identified in each suppressed *fcho-1* mutant strain is indicated. Only a subset of the mutations were assayed. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for complete list of suppressor mutations. All data represent the mean ± SEM. (**A**) Starvation assay (days required for a worm population to expand and consume the bacterial food). The AP2; *fcho-1* double mutants all exhibit faster starvation rates compared to *fcho-1* mutants alone (p \< 0.01, unpaired, two-tailed t-test n ≥ 9). (**B**) Cargo assay. Fluorescence from GFP-tagged cargo on plasma membrane of intestinal cells. Left and right panels indicate experiments conducted on different days. n ≥ 5; \*p \< 0.05 and \*\*p \< 0.01, unpaired, two-tailed t-test compared to fcho(−) alone; † data reported in [Figure 1E](#fig1){ref-type="fig"} caption. (**C**) FRAP assay. Average time constants for fluorescence recovery after photobleaching of GFP-tagged AP2. n ≥ 3; \*p \< 0.05, unpaired, two-tailed t-test compared to fcho(−) alone.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.007](10.7554/eLife.03648.007)10.7554/eLife.03648.008Figure 2---figure supplement 2.Dominant mutations in AP2 subunits identified in fcho-1 suppressor screen.(**A**) mu-'cup' contact mutations. \* spontaneous *fcho-1* suppressor. (**B**) sigma-beta contact mutations. (**C**) alpha backbone mutations. (**D**) phosphorylation site mutations. (**E**) other mutations near inter-subunit contacts.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.008](10.7554/eLife.03648.008)

*fcho-1* suppressor mutations promote protease-sensitive, open AP2 {#s2-3}
------------------------------------------------------------------

To determine if AP2 remains in the closed conformation in *fcho-1* mutants we devised an in vivo protease assay. The mu2 subunit of AP2 becomes sensitive to trypsin when the complex is incorporated into clathrin coats ([@bib25]; [@bib1]). The protease-sensitive segment is contained within ∼15 residues that are not resolved in crystal structures ([@bib31]; [@bib15]), but the boundaries of this segment are apposed to the internal face of the sigma subunit in the closed structure, and are exposed on the exterior of the complex in the open structure ([Figure 3A](#fig3){ref-type="fig"}). Because this poorly conserved region tolerates the insertion of various tags ([@bib28]; [@bib20]), we inserted a TEV cleavage site in this sequence, and replaced the endogenous *apm-2* gene with the protease-sensitive version of mu2 tagged with HA ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We used a temperature-inducible promoter to transiently drive expression of TEV protease in these transgenic worms. After heat-shock induction of the protease, the level of the full-length subunit declined and a smaller 25kd N-terminal fragment accumulated over a 8 hr period ([Figure 3B,C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}) The mu2 cleavage rate was slower in *fcho-1* mutants even though the protease was induced to a similar level ([Figure 3B,C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B-D](#fig3s1){ref-type="fig"}). TEV-sensitivity was also demonstrated for a FLAG-tagged version of mu2, which was used in the structure-function experiments described below ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These data suggest that a larger fraction of AP2 is in the closed, protease-resistant state in *fcho-1* mutants.10.7554/eLife.03648.009Figure 3.FCHo promotes the protease-sensitive open conformation of AP2 in vivo.(**A**) A TEV protease site was inserted into a surface loop of the mu domain. The dashed line connects the boundaries of the unstructured region within two conformations of the AP2 complex. (**B**) Western blot of whole animal lysates expressing the HA-tagged mu2 subunit depicted in [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}. The amount of full-length subunit (top) decreases following heatshock. Anti-histone blot is below. Each sample is comprised of 100 larval 4 stage animals. (**C**) Quantification of mu2 proteolysis. Intensity of anti-HA signal relative to histone, normalized to time 0. \*p \< 0.05, unpaired, two-tailed t-test compared to fcho(+) values at same time point, n = 4. Data represent the mean ± SEM. See [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for results using FLAG-tagged version of mu2.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.009](10.7554/eLife.03648.009)10.7554/eLife.03648.010Figure 3---figure supplement 1.Schematic of TEV Protease assay and results from FLAG-tagged version of mu2.(**A**) Cartoon of modified mu2 including epitope tag, sigma-homology domain, mu domain and TEV protease site insertion. The protease site is predicted to become more accessible upon AP2 activation. (**B**) Western blots of whole worm lysates. Animals were heat-shocked for one hour to induce TEV protease expression. Full-length (intact) and proteolyzed (cleaved) mu2 subunits were detected using anti-FLAG (top) while protease expression was monitored with anti-TEV (middle). Anti-histone blot (bottom) used for normalization. Each sample is comprised of 100 larval 4 stage animals. (**C**) Quantification of the proteolysis. Intensity of intact mu2 relative to histone, normalized to time 0. Similar results were obtained using an HA-tagged mu2 subunit ([Figure 3B,C](#fig3){ref-type="fig"}). (**D**) Protease levels over time. Intensity of TEV band relative to histone.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.010](10.7554/eLife.03648.010)

We also examined the conformation of AP2 in the strains carrying the *fcho-1* suppressors using the TEV protease assay ([Figure 4A,C](#fig4){ref-type="fig"}). We tested two suppressors each for the alpha, beta and mu2 subunits, and each led to an increase in mu2 cleavage in the double mutants compared to fcho(−) alone ([Figure 4C](#fig4){ref-type="fig"}). These data suggest that AP2 is in the closed conformation in the absence of FCHo and that single amino acid changes in the complex are sufficient to tip the equilibrium toward the active conformation. Indeed, the amount of rescue observed in the cargo assay ([Figure 4B](#fig4){ref-type="fig"}) was grossly correlated with protease sensitivity. However, none of these mutations fully restored cargo endocytosis, even though all of the suppressors rescued growth and morphology ([Figure 4A](#fig4){ref-type="fig"} and not shown). Only the mutation that resulted in a profoundly protease--hypersensitive complex (μE306K) increased cargo internalization with high significance in *fcho-1* mutants. These findings indicate that subtle conformational changes favoring active AP2 satisfied an organismal requirement for FCHO-1 without fully compensating for the endocytic defect of *fcho-1* mutants.10.7554/eLife.03648.011Figure 4.AP2 mutations restore the active conformation in *fcho-1* mutants.Listed mutations correspond to the worm residues. (**A**) Starvation assay (days required for a worm population to expand and consume the bacterial food). (**B**) Cargo assay (amount of GFP-tagged cargo on intestinal cell membrane). For (**A**) and (**B**), data represent the mean ± SEM for n ≥ 10. Significance determined by unpaired, two-tailed t-test compared to fcho(−), \*p \< 0.05 and \*\*p \< 0.01. (**C**) in vivo TEV protease assay. Samples collected for Western blot analysis 8 hr after heatshock (as in [Figure 3B](#fig3){ref-type="fig"}). Numbers indicate band intensity of full-length mu2 (anti-HA, top) relative to histone (bottom), normalized to the fcho(+) sample. (**D**) Blot for phosphorylated threonine-160 (T156 in vertebrates) in the linker region of the mu2 subunit. Samples collected before heatshock. Numbers indicate band intensity of phosphorylated T160 (top) relative to histone (bottom), normalized to fcho(+) sample. For (**C**) and (**D**), each sample is comprised of 100 larval 4 stage animals.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.011](10.7554/eLife.03648.011)10.7554/eLife.03648.012Figure 4---figure supplement 1.Activation of AP2 strengthens membrane association, enables cargo binding, and stabilizes the location of mu2 phosphorylation.(**A**) and (**B**) are adapted from ([@bib20]). (**A**) Side views of the AP2 complex showing that the mu2 linker (pink dashed line) containing the phosphorylation site (T160) transitions from a disordered state (closed, left) to ordered helix (open, right) upon activation. The conformational rearrangement is associated with enhanced membrane binding and exposure of a binding pocket for transmembrane cargo (YxxΦ). (**B**) Location of threonine-160 (156 in vertebrates) of mu2 linker in open conformation of AP2. The residue is at the end of a helix (pink) that nestles into a groove in the beta subunit (green). Mutations isolated as *fcho-1* suppressors are indicated, as is the hydroxyl group (red) predicted to be phosphorylated.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.012](10.7554/eLife.03648.012)

Phosphorylation of AP2 is downstream of *fcho-1* function {#s2-4}
---------------------------------------------------------

The vertebrate mu2 subunit is phosphorylated in a clathrin-dependent manner at threonine-156 by Adaptor-Associated Kinase (AAK1) ([@bib32]; [@bib6]; [@bib7]; [@bib19]). The phosphorylated core complex binds cargo motifs and phosphoinositides with higher affinity ([@bib18]). In the *fcho-1* suppressor screen we isolated multiple mutations in the equivalent residue (T160) of the worm mu2 subunit, including a mutation to the phosphorylation-defective amino acid alanine ([Figure 4A](#fig4){ref-type="fig"}, [Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}). Mutating this residue to the phosphomimetic residue glutamate also suppressed *fcho-1* mutants ([Figure 4A](#fig4){ref-type="fig"}). Note that cargo internalization was compromised in both the phosphorylation-defective and phosphomimetic mutants ([Figure 4B](#fig4){ref-type="fig"}), which is consistent with previous reports ([@bib30]; [@bib38]; [@bib20]). Our data suggest that the presence of a threonine at this position stabilizes the inactive state and that any change to this residue is likely to destabilize the inactive state of AP2.

To assay phosphorylation of the mu2 subunit, we used an antibody specific to phosphorylated T160. We found that AP2 is phosphorylated in the wild-type, and is hypo-phosphorylated in the *fcho-1* mutant ([Figure 4D](#fig4){ref-type="fig"}). All of the suppressor mutations we tested increased phosphorylation relative to the *fcho-1* mutants (except of course the T160 mutations themselves). Increased phosphorylation was also associated with increased protease sensitivity of the mu2 subunit in the TEV assay ([Figure 4C](#fig4){ref-type="fig"}). These data demonstrate that the open state is phosphorylated, and that FCHO-1 is not absolutely required for phosphorylation, but rather AP2 in the active state is sufficient to induce phosphorylation. Nevertheless, this threonine residue is not completely exposed in the crystal structure of the open conformation ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) ([@bib20]) so it is unclear whether the side chain would be accessible to AAK1 in this state.

A compensatory salt bridge mutation restores *fcho-1* mutant phenotypes {#s2-5}
-----------------------------------------------------------------------

The protease sensitivity of the suppressor mutations indicates that the closed structure determined by X-ray crystallography is an authentic structure in vivo, and that these mutations destabilize the closed state of AP2. Nevertheless, it is possible that the mapping of these mutations onto the crystal structure is coincidental. To verify that the closed structure has in vivo significance we identified a mutation among our suppressors that would disrupt a salt bridge in the closed conformation, and used the crystal structure to predict a compensatory mutation that would restore the salt bridge. In the closed conformation β (E361) forms a salt bridge to μ (K411) ([Figure 2A](#fig2){ref-type="fig"}; [Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We therefore analyzed mutations in β (E361K) and μ (K411E) that break this salt bridge, and found that both suppressed the *fcho-1* mutant phenotype ([Figure 5B](#fig5){ref-type="fig"}). These mutations also increased protease sensitivity relative to the *fcho-1* mutant, and increased phosphorylation of threonine-160 ([Figure 5D,E](#fig5){ref-type="fig"}). Similar to previous results ([Figure 4](#fig4){ref-type="fig"}), only the mutation that produced an acutely open complex (μK411E) significantly rescued the cargo-recycling defect of *fcho-1* mutants ([Figure 5C](#fig5){ref-type="fig"}). We then constructed the double mutant containing both the βE361K and μK411E mutations which should restore the salt bridge. The two mutations together no longer suppressed the *fcho-1* growth phenotype or cargo retrieval defect of the *fcho-1* mutants, and reversed the protease sensitivity of the single mutants. Phosphorylation of T160 in the double mutant was reduced relative to the μK411E single mutant but was not fully restored to fcho(−) levels. These results confirm that the closed form as determined by crystallography predominates in the *fcho-1* mutant and that destabilizing the closed form can bypass the requirement for FCHO-1.10.7554/eLife.03648.013Figure 5.Charge swaps activate and inactivate AP2 in vivo.(**A**) Predicted location of residues stabilizing an important inter-subunit salt bridge within the inactive (PBD ID: 2VGL) crystal structure of the vertebrate AP2 core complex. Alpha is blue, beta is green, and mu2 is pink. The residue numbers are from the worm subunits. See [Figure 2A](#fig2){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} for localization on interfaces. (**B**) Starvation assay (days required for a worm population to expand and consume the bacterial food). AP2 mutations indicated above. (**C**) Cargo assay (amount of GFP-tagged cargo on intestinal cell membrane). For (**B**) and (**C**), data represent the mean ± SEM for n ≥ 10. Significance determined by unpaired, two-tailed t-test, \*\*p \< 0.01. (**D**) in vivo TEV protease assay. Samples collected for western blot analysis (anti-HA) 8 hr after heatshock (As in [Figure 3B](#fig3){ref-type="fig"}). Numbers indicate band intensity normalized to the fcho(+) sample. (**E**) Blot for phosphorylated threonine 160. Samples collected before heatshock. Numbers indicate band intensity normalized to fcho(+) sample.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.013](10.7554/eLife.03648.013)10.7554/eLife.03648.014Figure 5---figure supplement 1.An Inter-subunit salt bridge is broken in the active conformation of AP2.Predicted location of the modified worm residues within the inactive (PBD ID: 2VGL) and active (PBD ID: 2XA7) crystal structures of the vertebrate AP2 core complex. Alpha is blue, beta is green, mu2 is pink, and sigma is cyan. The residue numbers are from the worm subunits. The residues are hidden in both of these views.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.014](10.7554/eLife.03648.014)

A conserved segment in the FCHo linker domain opens AP2 {#s2-6}
-------------------------------------------------------

Which domain of FCHo activates AP2? FCHO-1 is composed of a membrane-binding F-BAR domain ([@bib17]), a linker region, and a C-terminal μ-homology domain related to the medium subunit of AP2 ([@bib35]) ([Figure 6A](#fig6){ref-type="fig"}). We generated single copy transgenic animals expressing proteins deleting each of these domains in the *fcho-1* null background. We found that the N-terminal F-BAR domain is dispensable for rescue of all *fcho-1* phenotypes ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A-D](#fig6s1){ref-type="fig"}). Constructs lacking the C-terminal μ-homology domain (μHD) failed to rescue cargo endocytosis, but increased the growth rate, protease sensitivity and phosphorylation of the mutants ([Figure 6B](#fig6){ref-type="fig"}). However, deletions that extend into the linker domain failed to rescue *fcho-1* mutants. The linker domain was previously found to bind the AP2 complex using pulldown assays ([@bib44]), suggesting that the activation of AP2 by FCHO-1 observed here could be via a direct interaction.10.7554/eLife.03648.015Figure 6.A Conserved region of FCHo proteins is necessary and sufficient to rescue *fcho-1* mutants.(**A**) FCHo homologs showing conserved domains. Amino acid numbers indicated above. The AP2 Activator (APA) domain is aligned below. Amino acids colored by Clustal X scheme and shaded by conservation. Membrane Phospholipid-binding domain (MP), μ-Homology Domain (μHD). (**B**) Structure/function analysis of worm FCHO-1. (**C**) Quantification of *fcho-1* mutant rescue with APA domains from worm (*Ce*), mouse (*Mm*), and human (*Hs*) orthologs expressed as extrachromosomal arrays. See [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"} for results of the starvation assay when the APA domains are expressed from single-copy transgenes. For (**B**) and (**C**), protease assay performed with FLAG-tagged mu2 subunit as in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}. Numbers indicate band intensity of full-length mu2 (top) relative to the histone control (bottom) and normalized to the fcho(+) sample.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.015](10.7554/eLife.03648.015)10.7554/eLife.03648.016Figure 6---figure supplement 1.The APA domain of FCHO-1 Is sufficient to organize AP2 on the membrane.ΔBAR represents worm FCHO-1 (amino acids 288--968) lacking the F-BAR domain expressed from a single-copy transgene while APA represents amino acids 454--565 overexpressed by an extrachromosomal (See [Figure 6](#fig6){ref-type="fig"}). (**A**) Distribution of the alpha-GFP pixel intensities in maximum Z-projections of coelomocyte halves as in [Figure 1B](#fig1){ref-type="fig"} († data reproduced from [Figure 1B](#fig1){ref-type="fig"}). Arrow indicates higher intensity pixels that are missing in *fcho-1* mutants. (**B**) The percent coefficient of variance of the alpha-GFP pixel intensities in coelomocytes († data reproduced from [Figure 1B](#fig1){ref-type="fig"}). (**C**) FRAP assay. Fluorescence of membrane regions of coelomocytes expressing alpha-GFP photobleached at time = 0. (**D**) Time constants for recovery of fluorescence after photobleaching. Data represent mean ± SEM of n = 9--15 coelomocytes for (**A**) and (**B**), and n = 8--20 coelomocytes for (**C**) and (**D**); \*\*p \< 0.01 unpaired, two-tailed t-test compared to fcho(−).**DOI:** [http://dx.doi.org/10.7554/eLife.03648.016](10.7554/eLife.03648.016)

The linker domain of FCHO-1 is poorly conserved in general, but there is a small region of ∼90 amino acids that is shared with other FCHo homologs and the vertebrate protein SGIP1 ([Figure 6A](#fig6){ref-type="fig"}) ([@bib35]; [@bib43]). Expression of this short fragment alone was capable of rescuing *fcho-1* mutants, including growth rate, endocytosis of cargo, and morphology ([Figure 6C](#fig6){ref-type="fig"}, [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}, and not shown). This fragment is also sufficient to immobilize AP2 on the membrane in the photobleaching assay and to cluster AP2 into presumptive endocytic pits ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Moreover, the equivalent domains from mouse FCHo2, mouse SGIP1, and human FCHo1 also rescued *fcho-1* mutants ([Figure 6C](#fig6){ref-type="fig"}), though the fragment from mouse FCHo1 rescued poorly ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). These results suggest that this small 90 amino acid region, called the [AP]{.ul}2 [A]{.ul}ctivator motif (APA), encompasses a large fraction of FCHO-1 function in vivo.

To determine whether the APA domain binds AP2, we expressed the worm and mammalian APA domains fused to a HaloTag in tissue culture cells (HEK293) and pulled down the APA fragment using chloroalkane beads. Silver-stained gels ([Figure 7A](#fig7){ref-type="fig"}) and Western blot analysis ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) suggested the presence of all four AP2 subunits in the pulldowns. To systematically identify the binding partners we performed a mass spectrometry analysis of the pulldowns using Multi-Dimensional Protein Identification Technology (MudPIT). The majority of the peptide reads were from the bait itself ([Figure 7B](#fig7){ref-type="fig"}), but the most abundant interacting partner for the APA domains from mouse FCHo2 and SGIP1 was the AP2 complex (∼10% of peptides, [Figure 7B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). When the bait included the entire FCHo2 or SGIP1 proteins (or FCHo2 without the BAR domain), AP2 was still enriched; but additional components known to bind the μ-homology domain, such as Eps15, were also isolated ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). The interaction of the APA domain with AP2 likely occurs in vivo as well, since fluorescently tagged APA colocalizes with AP2 on the membrane in coelomocytes, and membrane association is lost in mutants lacking the mu2 subunit ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}).10.7554/eLife.03648.017Figure 7.The APA domain binds AP2.In (**A**) and (**B**) APA domains from FCHo homologs were expressed as HaloTag fusions in HEK293T cells (*Ce*, *C. elegans*; *Mm*, *M. musculus*). (**A**) Silver-stained gel of affinity-purified proteins following proteolytic cleavage from the HaloTag. Arrows indicate bands of presumed identity. (**B**) The top ten human proteins purified using two different APA baits, as detected by MudPIT mass spectrometry. Nonspecific proteins also found in the control were removed. Values represent the mean % distributed Normalized Spectral Abundance Factor (dNSAF × 100) from three independent experiments. The values of all four AP2 subunits were totaled to determine the amount of complex in each sample. Multiple isoforms of alpha, beta, and phosphatidylinositol 5-phosphate 4-kinase type-2 (PIP4K2) were summed. WD repeat-containing protein 48 (WDR48), epidermal growth factor receptor substrate 15 (EPS15), adaptin ear-binding coat-associated protein 2 (NECAP2), and serine/threonine-protein kinase PLK1 (PLK1). See [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"} for complete results. (**C**) APA pulldowns using bacterially expressed proteins. Purified HaloTag with (HT + APA) and without (HT) the APA domain from mouse SGIP1 were incubated with purified AP2 fragments followed by TEV protease cleavage to release the APA bait. Silver-stained gel of the eluted proteins. Note that the alpha/sigma and beta/mu hemicomplexes are soluble in our hands and that the AP2 appendage (ear) domains exhibit non-specific binding in this assay.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.017](10.7554/eLife.03648.017)10.7554/eLife.03648.018Figure 7---figure supplement 1.The APA domain links FCHo proteins to the AP2 complex.(**A**) Starvation assay of *fcho-1* mutant worms expressing APA domains as single-copy transgenes. Data represent mean ± SEM of n = 10 plates. \*p \< 0.05 and \*\*p \< 0.01 compared to fcho(−) worms, determined by unpaired, two-tailed t-test. (**B**) Western blot for AP2 subunits purified from HEK293T cells using FCHo1 linker regions and APA domains as bait. APA domain from FCHo2 included for comparison (far right). Blots were incubated with antibodies for all four subunits and detected using secondary antibodies for mouse (top) and rabbit (bottom). Weak binding of the mouse FCHo1 APA fragment to AP2 (See also [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}) was associated with weak rescue of *fcho-1* mutants in (**A**). This result was not consistent with conservation of the APA domain ([Figure 6A](#fig6){ref-type="fig"}) and a previous report that the linker region of human FCHo1 binds AP2 ([@bib44]). Indeed, the linker regions from mouse, human and zebrafish FCHo1 homologs affinity-purified AP2 (left), and the APA domain from human FCHo1 bound AP2 (middle) and rescued *fcho-1* mutants better than the mouse fragment in (**A**). Note the cloned human fragment of APA is slightly larger than the mouse FCHo1 fragment, and this may account for differences in binding and rescue. For (**A**) and (**B**), *C. elegans* (*Ce*), *M. musculus* (*Mm*), *H. sapiens* (*Hs*), and *Danio rerio* (*Dr*). The APA domains are dark blue and the poorly conserved linker regions are gray. (**C**) Top ten human proteins purified using regions of FCHo proteins in addition to the APA domain as bait. ΔBAR lacks the N-terminal 278 amino acid F-BAR domain. Results from a single experiment reported as in [Figure 7B](#fig7){ref-type="fig"}. Epidermal growth factor receptor substrate 15 (EPS15), epidermal growth factor receptor substrate 15-like (EPS15L), sorting nexin-9 (SNX9), intersectin-1 (ITSN1), and growth factor receptor-bound protein 2 (GRB2). See [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"} for complete results. (**D**) Localization of APA in coelomocytes. Flourescently-tagged alpha subunit and APA domain from mouse SGIP1 were imaged in animals with and without the mu2 subunit. Intensity of each signal along the indicated line is plotted.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.018](10.7554/eLife.03648.018)10.7554/eLife.03648.019Figure 7---figure supplement 2.Top proteins detected by MudPIT analysis.The top 10 proteins (in addition to bait) detected by MudPIT in samples purified from HEK293 cells using mouse FCHo2 and SGIP1 proteins (full-length and fragments) as bait. The ranked frequency of detection for each non-bait (*H. sapiens*) protein is indicated (Five leftmost columns). The amount of each protein present in the sample is reported as the percent distributed Normalized Spectral Abundance Factor (%dNSAF) along with the corresponding values from *C. elegans* FCHO-1 APA and control (HaloTag alone) samples (16 rightmost columns). Note that results from three separate experiments using the mouse APAs and negative control are reported. The wide middle column describes the Halo-tagged baits and associated human proteins. The subunits of the AP-2 complex (yellow) are detected in the top 10 proteins of most purifications. The AP2A2 and AP1B1 isoforms (light yellow) are less abundant (detected with one peptide unique to these isoforms). *M. musculus (Mm), C. elegans (Ce)*, AP2 activator domain (APA), full-length (FL), lacking the F-BAR domain (ΔBAR), not-detected (X). See 'Materials and methods' for more information.**DOI:** [http://dx.doi.org/10.7554/eLife.03648.019](10.7554/eLife.03648.019)

We demonstrated that the interaction between the APA domain and the AP2 core is direct using purified recombinant proteins in pulldown assays ([Figure 7C](#fig7){ref-type="fig"}). The APA domain does not appear to bind the appendages of the large adaptins, nor to the mu domain alone. Rather, it bridges the complex since the APA bait binds both the alpha/sigma and beta/mu hemicomplexes. Together these data suggest that the APA domain in FCHo homologs from worms, mice and humans binds AP2 to destabilize the closed conformation and promote the active conformation.

Discussion {#s3}
==========

Mutations in the FCHo gene were found to phenocopy loss of AP2 subunits in the nematode *C. elegans*, suggesting these proteins act in a single pathway. We found that FCHo acts upstream of AP2: the function of FCHo can be bypassed by constitutively open mutations in the AP2 complex. Moreover the effect of FCHo on AP2 is direct: a 90 amino acid fragment of the linker domain in the FCHo family proteins binds AP2. This activator fragment is necessary and sufficient for rescue when overexpressed in *fcho-1* mutants.

FCHo acts on AP2 {#s3-1}
----------------

There is broad agreement that FCHo acts early and it acts to stabilize nascent clathrin-coated pits via AP2. The AP2 complex associates with the plasma membrane with different lifetimes; some AP2 clusters are aborted rapidly (between 5--16 s) whereas others develop into fully committed pits (90 s) ([@bib24]). In the absence of FCHo, the lifetime of AP2 at the membrane in cultured cells is quite brief (\<10 s), whereas overexpression of FCHo stabilizes AP2 and promotes the growth of clathrin-coated pits with long lifespans (\>25 s) ([@bib16]; [@bib4]). We observe a similar phenotype in *fcho-1* mutants: although AP2 still associates with the plasma membrane, it does not form clusters. Moreover, the dwell time of AP2 on the membrane is shorter; in *fcho-1* mutants worms, the lifespan of AP2 on the membrane is reduced from 35 to 10 s. These results are strikingly similar to the observations of Cocucci et al (2012).

Previously it was thought that FCHo stabilizes AP2 on the membrane indirectly by binding Eps15 and intersectin, and these proteins in turn bind AP2 and stabilize the formation of a clathrin-coated pit ([@bib16]). Our data suggest that FCHo acts directly on AP2: a 90 amino acid segment of the linker domain binds the AP2 complex in pulldowns from HEK293 cells. The linker region of human FCHo1 was previously shown to interact with AP2 ([@bib44]). This interaction was thought to be via the appendage domain of the alpha subunit of AP2, however we find that the interior of the linker binds the core complex. This AP2 activator domain (APA) is conserved and this fragment from the nematode FCHO-1 protein or from the mammalian FCHo1, FCHo2 and SGIP1 proteins can rescue *fcho-1* mutant worms. It is curious to note that while the APA domain is conserved in metazoan orthologs of FCHO-1, it is absent in the yeast ortholog Syp1p ([@bib35]).

What is the function of the μ-homology and F-BAR domains in *C. elegans*? Although the APA domain rescues *fcho-1* mutants to grossly wild-type morphology and behavior, it does not fully rescue at a cellular level: endocytosis of cargo is not restored to wild-type levels by expression of the APA fragment. Full rescue is only observed when the rescuing constructs include both the APA domain and the μ-homology domain. We have confirmed that the μ-homology domains of FCHo proteins bind Eps15 and Eps15-like proteins in pulldowns from HEK293 cells by extending the bait proteins to include this domain ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). It is therefore likely that binding of FCHo to Eps15 is required for endocytosis of cargo. It has been demonstrated that FCHo forms an independent complex with Eps15 and Intersectin and that this complex functions in the recruitment of cargo to clathrin-coated pits ([@bib26]).

The F-BAR domain binds membrane and is required to recruit FCHo to the cell surface in both yeast and tissue culture cells ([@bib35]; [@bib39]; [@bib16]). By contrast, neither the F-BAR domain of FCHO-1 or the membrane association domain of SGIP are required for rescue of *fcho-1* mutants. The dispensable nature of the F-BAR domain conflicts with models in which this domain must bend the membrane for clathrin-coated pit formation ([@bib16]), and instead suggests that the most important feature of the F-BAR domain is its ability to localize the APA domain to the membrane. Apparently in *C. elegans*, the APA domain of FCHo can be recruited to the membrane via interactions with other proteins independent of the F-BAR domain. Nevertheless, the presence of a membrane-binding motif in all FCHo and SGIP proteins demonstrate that membrane interactions are important and conserved.

Open AP2 bypasses the requirement for FCHo {#s3-2}
------------------------------------------

Different crystal structures of AP2 suggest that the complex can adopt multiple conformations. AP2 can assume a closed and inert conformation in which membrane- and cargo-binding domains are inaccessible ([@bib5]), in the unlatched or open conformations AP2 can bind the plasma membrane and the recognition motifs of cargo ([@bib22]; [@bib20]).

The gain-of-function mutations in AP2 that bypass the requirement for *fcho-1* provide in vivo support for these conformational changes. These mutations can be sorted into three classes based on the regions affected: the latch, the bowl and the hinge. In the unlatched state, the N-terminus of the beta subunit disconnects from the alpha and sigma2 subunits and exposes the dileucine-motif binding pocket ([@bib22]). Among the bypass suppressors of *fcho-1* were seven residues at the contact interface of the latched state. In the open structure, the mu domain is expelled from the bowl formed by the other subunits, and about half of the suppressors (34/71) were found in contact residues between mu2 and the bowl. The alpha hinge domain flexes as the bowl collapses in the open state, and 19 mutations in the alpha hinge were identified. We isolated 7 other mutations in residues that reside near inter-subunit contacts in the closed conformation. These mutations are all consistent with a destabilization of the closed state, and are in fact in an open state as determined by the exposure of a TEV protease site in vivo.

The activated AP2 mutations that result in the most open (protease sensitive) and phosphorylated AP2 complex fully rescue the morphological and growth defects of the *fcho-1* deletion. Nevertheless, these mutations do not fully restore clearance of an artificial cargo from the surface of the intestine. It is likely that the activated AP2 mutations cannot recapitulate all of the normal functions of the AP2 complex, since it is known that FCHo has other functions beyond its actions on AP2, for example via interactions with Eps15 or Disabled-2 ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"} and [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) ([@bib35]; [@bib16]; [@bib43]; [@bib27]; [@bib44]; [@bib26]). Nor do these mutants exhibit enhanced endocytosis or membrane association in an otherwise wild-type background ([Figure 8](#fig8){ref-type="fig"}). It is possible that compensatory mechanisms counteract the open state of these AP2 mutants. Alternatively, our endocytosis assay may be at its detection limit because fluorescence from the artificial cargo is close to background levels in the wild-type.10.7554/eLife.03648.020Figure 8.*fcho-1* bypass mutants do not exhibit hyperactive AP2.Mutations were examined in an fcho(+) background. (**A**) Cargo assay. Amount of GFP-tagged cargo on intestinal cell membrane. (**B**) FRAP assay. Time constants for recovery of alpha-GFP fluorescence after photobleaching. (**C**) The percent coefficient of variance of alpha-GFP pixel intensities in coelomocytes. Data represent mean ± SEM of n = 9--13 intestinal cells for (**A**) and n = 9--14 coelomocytes for (**B**) and (**C**); \*\*p \< 0.01 unpaired, two-tailed t-test compared to fcho(+).**DOI:** [http://dx.doi.org/10.7554/eLife.03648.020](10.7554/eLife.03648.020)

The only mysterious suppressors are the mutations at the phosphorylation site on the mu2 subunit. The other suppressors led to an increase in phosphorylation of T160, consistent with phosphorylation promoting the open state ([@bib9]; [@bib30]; [@bib36]). However, mutation to a phosphodefective, as well as a phosphomimetic, amino acid caused AP2 to adopt the open state. These data are most consistent with dephospho-threonine at this position stabilizing the closed state. Phosphorylation then does not cause the open state but rather is a result of the open state. This conclusion is supported by the observation that clathrin assembly stimulates AAK1 to phosphorylate mu2 ([@bib7]; [@bib19]).

How then does FCHo promote the AP2 cycle? The formation of a closed form of AP2 is probably required to unbind membranes from newly endocytosed vesicles and to scan the membrane for new sites of endocytosis. The coincidental presence of FCHo, cargo, and PIP2 can then stabilize the open state, and the conformational changes in the complex then nucleate recruitment of clathrin and other pit components ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) ([@bib20]; [@bib21]).

Materials and methods {#s4}
=====================

Strains {#s4-1}
-------

Worm strains were cultured and maintained using standard methods ([@bib3]). A complete list of strains and mutations used is in the Extended Strains List ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}).

Jowls screen {#s4-2}
------------

*C. elegans* late L4s were mutagenized for 4 hr at 22°C in 0.2 mM EMS. ∼50,000 haploid genomes were screened in the F~2~ and F~3~ generation to isolate animals exhibiting the jowls phenotype. Genomic DNA was prepared from the offspring of these animals for amplification and subsequent sequencing of AP2 subunits. Mu2 subunit (*apm-2*) primer pairs were oGH408-9, oGH411-452, and oGH412-3. Alpha subunit (*apa-2*) primer pairs were oGH414-5, oGH416-7, and oGH418-9. Sigma2 subunit (*aps-2*) primer pair was oGH430-2. Beta subunit primer pairs were oGH441-2, oGH443-4, oGH445-6 and oGH447-8. To identify *fcho-1* mutants, PCR products corresponding to the coding sequences of the gene were amplified and sequenced using primer pairs oGH420-1, oGH423-50, oGH424-5, oGH428-9, and oGH433-51. Oligonucleotide sequences are listed in [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}.

*fcho-1* alleles {#s4-3}
----------------

The targeted deletion allele of *fcho-1* was generated by mobilizing a *Mos1* transposon from the gene (*ttTi3855*) and repairing the double strand break with a DNA template that replaces the first eight exons of *fcho-1* with an *unc-119*(+) transgene in an *unc-119(ed3)* mutant strain ([@bib11]). The repair template plasmid was generated by Three-Fragment Multisite Gateway (Invitrogen, Carlsbad, CA). The proximal targeting arm (2.1 kb) was amplified (oligos oMT1-2, Mengyao Tan, University of Utah, Salt Lake City, UT) and cloned into the \[2--3\] donor. The distal arm (2.1 kb) was amplified with oMT3-4 and cloned into the \[4--1\] donor. The targeting arm entry clones were assembled with a \[1--2\] entry containing *unc-119(+)* (pRL8, Rachel Lofgren, University of Utah) in the \[4--3\] destination using *LR* clonase (Invitrogen). The resulting repair template was injected into *ttTi3855* II; *unc-119(ed3*) III worms along with additional plasmids (transposase and array markers) as previously described in ([@bib11]) The molecular identity of the *dx34* allele was determined by whole genome sequencing (Illumina, San Diego, CA); *dx34* deletes the 3ʹ end of *fcho-1*, the downstream gene *vig-1* and the 5ʹ end of *jip-1*. Additional mutant alleles of *fcho-1 (ox500\[Q634X\], ox504 \[frameshift\], ox620\[K872X\], ox619\[W882X\])* were isolated in the jowls screen (See above). Worm strains, plasmids and oligonucleotide sequences are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

*fcho-1* suppressor screen {#s4-4}
--------------------------

*fcho-1(ox477)* mutants were mutagenized for 4 hr at 22°C in 0.5 mM ENU. After washing with M9 buffer, ∼100 L4 to young adult animals were pipetted onto 10 cm Normal Growth Media (NGM) agar plates previously seeded with 1 ml of a dense bacterial culture (OP50). After starvation, ∼2 × 2 cm pieces of each plate were transferred to a fresh NGM agar plate with bacteria. This process was repeated 3--4 times to select for genotypes with greater fitness than the starting strain. ∼10 worms were selected from each plate exhibiting a faster rate of food consumption than sibling plates. Genomic DNA was prepared from the offspring of these animals for amplification and sequencing of AP2 subunits. Males of *fcho-1* suppressor strains were generated by heatshock and crossed to *fcho-1* mutant hermaphrodites to score dominance and sex chromosomal linkage of the suppressor mutations in the F~1~ offspring. *ox618* was isolated as a spontaneous suppressor. Worm strains are listed in [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}.

Preparation of worms for microscopy {#s4-5}
-----------------------------------

Worms were immobilized for fluorescence microscopy by placing them in a 1:1 mixture of a 1 μm polystyrene bead slurry (Polysciences, Warrington, PA) and 2× PBS pH 7.4 on 8--10% agarose pads ([@bib23]). Worms were allowed to equilibrate on the slide for 5 min before data were acquired. Data acquisition from each slide did not last longer than 20 min to ensure the health of the worms.

AP2 localization in coelomocytes {#s4-6}
--------------------------------

Worms expressing alpha adaptin-GFP (*oxSi254*) were imaged on an Ultraview VOX spinning disk confocal microscope (Perkin Elmer, Waltham, MA) with a 100× oil immersion objective (Carl Zeiss, Jena, Germany). A z-stack of half of the coelomocyte was acquired at maximum speed (200 ms exposure per slice) with 0.2 µm spacing. Fluorescence was excited with a 488 nm laser and was filtered through a 500--550 nm bandpass filter to an EMCCD (C9100-23B, Hamamatsu Photonics, Hamamatsu, Japan). The images were then analyzed using a set of custom written plugins (available at <http://research.stowers.org/imagejplugins>) in ImageJ (<http://rsbweb.nih.gov/ij/>). We started by creating a maximum intensity projection of the data. Next, the user specified an ROI inside the coelomocyte that does not include the outermost membrane. The mean intensity and standard deviation of the ROI was then measured for each time point. The coefficient of variance (%CV) was then calculated and averaged for all time points and all worms per sample. Additionally, histograms of pixel intensities inside the coelomocytes were taken from the exact same ROI as the %CV measurements. The mode of a logarithmic histogram with a bin size of 1000 was used as the background intensity. The mode was then subtracted from the histogram. A value of 15,000 was then added back to the image and a new logarithmic histogram with bin size of 1000 was measured. This was necessary to avoid zero or negative values in the histogram. The bin width of the histogram was set to 1000 for all images, while the number of bins was allowed to vary. For each sample, all of the histograms were aligned to the mode and summed. Each point of the resulting histogram was then normalized to the integral of the histogram.

Fluorescence recovery after photobleaching {#s4-7}
------------------------------------------

FRAP data was recorded either on a Perkin Elmer Ultraview VOX spinning disk with a 63× 1.2 NA C-Apochromat water immersion objective or an LSM 780 confocal microscope with a 40× 1.1 NA C-Apochromat water immersion objective (Carl Zeiss). On both microscopes, fluorescence was excited with a 488 nm laser and emission was collected in the 500--550 nm range. On the LSM 780, emission was collected in photon counting mode range with a temporal resolution of 2 s and a pinhole close to 1 airy unit. Four images were acquired prior to bleaching of a manually selected ROI with maximum 488 nm laser power. On the spinning disk, emission was collected with an EMCCD camera (Hamamatsu C9100-23B). Five images were acquired at maximum speed (exposure 100--200ms) to determine the average fluorescence intensity of the coelomocyte membrane. Bleaching was then achieved over a user specified ROI, using a 488 nm laser (the duration of bleaching was less than five seconds). Recovery images were then captured for 3 min with a rate of 1 image per second. Data was analyzed using a custom written plugin (available at <http://research.stowers.org/imagejplugins>) for ImageJ (<http://rsbweb.nih.gov/ij/>). This macro first registered the image sequences to compensate for movement of the worm/coelomocyte. Then the user specified the bleach ROI. The mean intensity of the ROI was then plotted per time point. A fit to the data was achieved with a one component fluorescence recovery model. The tau (inverse rate) values from the fits were then averaged for all worms per sample. For average plots of fluorescence recovery, curves were normalized so that the minimum value was 0 and the maximum value was 1 prior to averaging.

Cargo assay {#s4-8}
-----------

Worms expressing the synthetic fluorescent cargo (GFP-CD4-YASV; *oxSi484*) were imaged on a LSM 780 confocal microscope (Carl Zeiss). A single cross-sectional Z-plane through the intestine was recorded. All of the images for a data set were recorded in a single session using the same laser settings. The images were analyzed in ImageJ. A segmented line was drawn on the basal-lateral membrane connecting intestinal segments 2 and 3, or rarely, 3 and 4. The average intensity along the line was recorded.

Brood size assay {#s4-9}
----------------

For each genotype, 10--12 L4 worms were singled to culture plates and transferred to a fresh plate every 12 hr. The transfers stopped when the worm burst (due to an egg-laying defect such as in AP2 mutants) or the worm started laying unfertilized oocytes (such as wild-type). The fertilized embryos from each animal were counted to determine the brood size. If the worm was lost during the transfer, the data were discarded.

Starvation assay {#s4-10}
----------------

NGM agar plates (60 mm) were seeded with 0.45 ml of bacterial culture (OP50 expanded overnight in 2xYT at 37°C without shaking). The bacterial lawns were grown at 22°C for 3 days. Three young adult hermaphrodites were placed on the bacteria and propagated at 22°C. Plates were examined daily until the worm population had consumed all of the bacteria and dispersed. Multiple (usually 10) plates were scored for each genotype.

Molecular visualization {#s4-11}
-----------------------

All structural representations in this paper were prepared with the PyMOL molecular graphics system, version 1.5.0.4 (Schrödinger, New York, NY; [www.pymol.org](http://www.pymol.org/)). PyMOL visualization scripts are available at <https://github.com/jorglab/Vu_AP2>.

TEV assay transgenes {#s4-12}
--------------------

A mini-gene encoding the mu2 subunit of AP2 (*apm-2*) was constructed using the Multisite Gateway System (Invitrogen). The *apm-2* cDNA was amplified by PCR using primers oGH634 and oGH635 and recombined with the \[1--2\] donor vector using BP clonase (Invitrogen) to generate the entry vector pGH442. The latter half of the cDNA was replaced with two genomic fragments corresponding to the last seven exons that were amplified with primer pairs oGH618-9 and oGH620-1. The PCR products were subsequently cloned into the *apm-2* cDNA entry vector amplified with oGH616-7 using the Gibson assembly protocol ([@bib13]) to generate pGH443. A TEV protease cleavage site (ENLYFQGS) was inserted after the codon encoding alanine-240 using primers oGH756-7 and the Gibson reaction to generate pGH444. One version of the \[1--2\] *apm-2* entry vector was appended at the amino terminus with an HA tag (YPYDVPDYA) followed by a flexible linker (GTGGTGGSGGTG) by sequential amplification using primers oGH753-699 and oGH737-699 followed by recombination with the \[1--2\] donor to generate pGH445. A 3X FLAG tag (DYKDHDGDYKDHDIDYKDDDDK) was attached to a separate version of the \[1--2\] *apm-2* entry vector using primers oGH814-5 followed by the Gibson reaction to generate pGH446. 1.3 kb of the *apm-2* promoter region was amplified using oGH785-6 and recombined with the \[4--1\] donor vector to generate pGH461. The 3ʹ untranslated region (UTR) of *apm-2* was amplified with oGH797-519 and cloned into the \[2--3\] donor via the BP recombination reaction to generate pGH462. The entry clones were recombined with the \[4--3\] destination vector pCFJ606 (Christian Frøkjær-Jensen, University of Utah) using *LR* clonase (Invitrogen) to generate the complete *apm-2* minigene in a MosSCI targeting vector ([@bib12]). The HA-tagged version is pGH447 and the Flag-tagged version is pGH448.

Mutations to the *apm-2* coding sequence of HA-tagged \[1--2\] *apm-2* minigene (pGH445) were introduced by PCR with primer pairs containing the mutation followed by the Gibson reaction to re-close the plasmid. The primer pairs and resulting \[1--2\] entry clones are oGH937-8 (pGH449) for E306K, oGH943-4 (pGH450) for K411E, oGH947-8 (pGH451) for R440S, oGH929-30 (pGH452) for T160A, and oGH931-2 (pGH453) for T160E. LR recombination with pGH461, pGH462, and pCFJ606, generated the MosSCI targeting vectors pGH454 for E306K, pGH455 for K411E, pGH456 for R440S, pGH457 for T160A, and pGH458 for T160E.

To generate an inducible TEV protease, a codon-optimized protease sequence containing two artificial introns was synthesized as two gBlocks (IDT, Coralville, IA) and assembled with the *hsp-16.41* promoter and *unc-54* 3ʹUTR to generate pGH459 by digesting pWD141 (M Wayne Davis, University of Utah) with BstBI and EcoRV to generate a vector backbone for the Gibson reaction. The subsequent *Phsp:TEV:unc-54UTR* sequence was amplified (oGH806-7) and inserted into pCFJ150 amplified with oGH751-2 using Gibson assembly to generate a MosSCI targeting vector called pGH460. See [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} for oligonucleotide sequences, plasmids, and worm strains.

FCHo structure/function transgenes {#s4-13}
----------------------------------

The full-length *fcho-1* cDNA (2.9 kb) was amplified (oGH323-4) and recombined with the \[1--2\] donor vector of the Multisite Gateway (Invitrogen) three-fragment system using BP clonase (Invitrogen). A tagRFP containing three artificial introns (Stefan Eimer, University of Freiburg, Freiburg im Breisgau, Germany), an engineered S158T mutation (Rob Hobson, University of Utah) and flanked by flexible linkers (N-term: STSGGSGGTGGS; C-term: GGTGGTGGSGGTG) was amplified (oCF590-1) and inserted after the start codon of the *fcho-1* cDNA using oGH350-352 to open the vector and the Gibson reaction to close it. An HA tag was inserted into the N-terminal linker of TagRFP by digestion with KpnI followed by ligation with two annealed oligos encoding the tag (oGH372-3). The resulting \[1--2\] entry clone encoding HA_TagRFP_wormFCHO-1(1-968) was pGH389. Deletions of *fcho-1* coding sequence corresponding to amino acids 1-287 (F-BAR), 1-535 (F-BAR + APA), 688-968 (μHD), and 287-968 (APA + μHD) were introduced to the \[1--2\] entry using PCR and Gibson assembly. The resulting plasmids were: pGH475 for FCHO-1(288-968), pGH388 for FCHO-1(536-968), pGH476 for FCHO-1(1-687), and pGH477 for FCHO-1(1-286).

For APA expression, sequences corresponding to the same regions used as bait in tissue culture cells (See previous section) were amplified (oGH793-4 for *C. elegans* FCHO-1, oGH808-9 for *M*us *musculus* FCHo2, oGH810-1 for *M. musculus* FCHo1, oGH812-3 for *M. musculus* SGIP1, and oGH1035-6 for *Homo* *sapiens* FCHo1) and inserted after the C-terminal linker of TagRFP using vector primers oGH649 and oGH781 with Gibson assembly. The resulting \[1--2\] entry clones were: pGH478 for worm FCHO-1(454-565), pGH479 for mouse FCHo2(306-394), pGH480 for mouse FCHo1(304-393), pGH481 for mouse SGIP1(97-184), and pGH482 for human FCHo1(305-402). All \[1--2\] entry clones were recombined with a \[4--1\] entry containing the ubiquitous *dpy-30* promoter, the *unc-54* 3ʹUTR in a \[2--3\] entry and one of two \[4--3\] destination vectors (pCFJ201 or pCFJ212) using LR clonase (Invitrogen) to generate MosSCI targeting vectors ([@bib12]). The resulting plasmids were: pGH394 for FCHO-1(1-968), pGH483 for FCHO-1(288-968), pGH393 for FCHO-1(536-968), pGH484 for FCHO-1(1-687), pGH485 for FCHO-1(1-286) pGH486 for FCHO-1(454-565), pGH487 for mouse FCHo2(306-394), pGH488 for mouse FCHo1(304-393), pGH489 for mouse SGIP1(97-184), and pGH490 for human FCHo1(305-402). See [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} for oligonucleotide sequences, plasmids, and worm strains.

Heatshock and western blot analysis {#s4-14}
-----------------------------------

Heatshock was performed by sealing worm plates with Parafilm and submerging them in a 34°C circulating water bath for 1 hr. For each sample, 100 or 200 L4 stage animals were selected and placed in microfuge tubes containing M9 buffer +0.001% Triton X-100. The worms were washed once with M9 buffer +0.001% Triton X-100 and collected by centrifugation (1000×g, 30 s) and placed on ice. All but ∼10 μl of the buffer was removed and 10 μl of LDS Sample buffer (4×, Novex, Invitrogen) with ∼100 mM fresh dithiothreitol was added. Samples were frozen in liquid N2 and stored at −80°C. Samples were then sonicated at 0°C for 6 min at 100% amplitude in a cup horn (Branson) and denatured at 99°C for 5 min. Entire lysates were loaded into NuPage 4--12% Bis-Tris Gels (Novex) for electrophoresis followed by transfer to nitrocellulose membranes using the iBlot system (Novex). For anti-HA blots, membranes were blocked in Tris Buffered Saline with 0.1% Tween 20 (TBST) and 5% milk powder. Anti-HA-Peroxidase High Affinity (3F10, Roche, Indianapolis, IN) was diluted 1:200 in TBST with 1% milk powder. Peroxidase was detected with ChemiGlow (Protein Simple, San Jose, CA) and imaged on a G:BOX (Syngene). For all other antigens, blocking and antibody incubations occurred in Odyssey Blocking Buffer (LI-COR, Lincoln, NE). Primary antibodies and dilutions include mouse anti-FLAG (1:1000, M2, Sigma-Aldrich, St. Louis, MO), rabbit anti-APM1 (phospho T156, 1:1000, Abcam 109397, Cambridge, England), rabbit anti-histone H3 (1:100000, Abcam 1791), and rabbit-anti TEV protease (1:500, Rockland Immunochemicals, Limerick, PA). Fluorescent secondary antibodies include goat anti-mouse IRDye 680LT (1:20,000, LI-COR) and goat anti-rabbit IRDye 800CW (1:15,000, LI-COR). All washes were performed in TBST. Band intensities were quantified using ImageStudioLite (LI-COR).

Affinity purification of proteins from tissue culture cells {#s4-15}
-----------------------------------------------------------

For preparation of samples for MudPIT analysis, sequences corresponding to the APA domains of FCHo proteins were inserted following the HaloTag (Promega, Madison, WI) sequence in a modified version of pcDNA5/frt ([@bib2]). The plasmid was linearized with PacI/PmeI and assembled using the Gibson reaction with each APA domain amplified from cDNA. The corresponding amino acids, primers and plasmids were 454--565 of *C. elegans* FCHO-1 (NM_061546.3; oGH828-9; pGH463), 306-394 of *M. musculus* FCHo2 (NM_172591.3; oGH830-1; pGH464), 304-393 of *M. musculus* FCHo1 (NM_028715.3; oGH832-3; pGH465), and 97-184 of *M. musculus* SGIP1 (AB262964.1; oGH834-5; pGH466). To identify proteins interacting with additional regions of FCHo proteins, amino acids 1-809 (oGH886-7; pGH467) and 263-809 (oGH887-892; pGH468) of *M. musculus* FCHo2 and 1-854 (oGH890-1; pGH469) of *M. musculus* SGIP1 were cloned. For western blot analysis of FCHo1 interactions, additional sequences encoding amino acids 267-609 of *M. musculus* FCHo1 (oGH1019-20; pGH470), 305-402 (oGH1039-40; pGH471) and 267-609 (oGH1021-2; pGH472) of *H. sapiens* FCHo1 (NM_001161357.1), and 295-390 (oGH1041-2; pGH473) and 260-609 (oGH1023-4; pGH474) of *Danio* *rerio* FCHo1 (XM_005166937.1) were also cloned into the same mammalian expression vector. Plasmids and oligonucleotides are listed in [Supplementary files 1B,C](#SD1-data){ref-type="supplementary-material"}, respectively. 150 mm dishes of HEK293T cells (∼80% confluent, Tissue Culture Core, Stowers Institute for Medical Research, Kansas City, MO) were transfected with 10 μg of plasmid using Lipofectamine 2000 (Invitrogen). 24--36 hr later, cells were washed with PBS, scraped from the dishes, collected by centrifugation and frozen at −80°C. Cell pellets were lysed and bound to HaloLink Magnetic Beads (Promega) according to the manufacturer\'s instructions. After washing the beads, complexes were released by incubation (2--3 hr at 22°C while shaking) with AcTEV protease (2 units in 100 μl, Invitrogen) to digest the cleavage site between the HaloTag and bait proteins. 20 μl of samples destined for MudPIT analysis were separated by electrophoresis and visualized using the Silver Stain Plus Kit (Bio-Rad, Hercules, CA). The remaining 80 μl were precipitated using trichloroacetic acid. For western blot analysis of FCHo1 interactors, 20 μl of purified complexes were electrophoresed, transferred, and blotted as described above using the following primary antibodies: mouse anti-alpha adaptin (610501; 1:2000; BD Biosciences, San Jose, CA), rabbit anti-AP2B1 (151961; 1:1000; Abcam), rabbit anti AP2M1 (75995; 1:1000; Abcam) and rabbit anti-AP2S1 (128950; 1:10000; Abcam).

MudPIT analysis {#s4-16}
---------------

TCA-precipitated proteins were urea-denatured, reduced, alkylated and digested with endoproteinase Lys-C (Roche) followed by modified trypsin (Promega) ([@bib45]; [@bib10]). Peptide mixtures were loaded onto 250 µm fused silica microcapillary columns packed with strong cation exchange resin (Luna, Phenomenex, Torrance, CA) and 5-μm C~18~ reverse phase (Aqua, Phenomenex), and then connected to a 100 µm fused silica microcapillary column packed with 5-μm C~18~ reverse phase (Aqua, Phenomenex) ([@bib10]). Loaded microcapillary columns were placed in-line with a Quaternary Agilent 1100 series HPLC pump and a LTQ linear ion trap mass spectrometer equipped with a nano-LC electrospray ionization source (ThermoScientific, San Jose, CA). Fully automated 10-step MudPIT runs were carried out on the electrosprayed peptides, as described in ([@bib10]). Tandem mass (MS/MS) spectra were interpreted using SEQUEST ([@bib8]) against a database consisting of 30,499 non-redundant human proteins (NCBI, 2012-08-27 release), 160 usual contaminants (human keratins, IgGs, and proteolytic enzymes), as well the mouse and *C. elagans* FCHo constructs and the mouse SGIP1 sequences. To estimate false discovery rates (FDR)s, the amino acid sequence of each non-redundant protein entry was randomized to generate a virtual library. This resulted in a total library of 61,327 non-redundant sequences against which the spectra were matched. Peptide/spectrum matches were sorted and selected using DTASelect ([@bib40]) with the following criteria set: Spectra/peptide matches were only retained if they had a DeltCn of at least 0.08, and minimum XCorr of 1.8 for singly-, 2.0 for doubly-, and 3.0 for triply-charged spectra. In addition, peptides had to be fully tryptic and at least seven amino acids long. Combining all runs, proteins had to be detected by at least two such peptides, or one peptide with two spectra. Under these criteria the averaged FDRs at the protein and peptide levels were 0.24% ± 0.2 and 0.44% ± 0.3, respectively. Peptide hits from multiple runs were compared using CONTRAST ([@bib40]). To estimate relative protein levels, distributed Normalized Spectral Abundance Factors (dNSAFs) were calculated for each detected protein/protein group, as described in ([@bib46]). The open source BioConductor package plgem in R was used to statistically compare the proteins detected in the FCHo and SGIP1 samples to negative controls ([@bib33]). Proteins were considered significantly enriched compared to the control datasets if their p-values for power law global error model signal-to-noise (PLGEM-STN) ratios were lower than 0.001, and they were detected in at least 2 out of 3 replicate analyses of the FCHo and SGIP1 purifications. The top 10 proteins (in addition to bait) were ranked based on decreasing PLGEM-STN values for FCHo2 APA, decreasing STN and dNSAF values for SGIP1 APA and full length (FL) SGIP1, and decreasing dNSAF values for FCHo2 FL and FCHo2 without the F-BAR domain (ΔBAR).

Recombinant protein purification and pulldown {#s4-17}
---------------------------------------------

The His-tagged beta-mu hemicomplex expression vector is pGH424: Sequence corresponding to trunk domain of mouse AP2 beta 1 (amino acids 1--591, NM_001035854) was amplified from mouse brain cDNA (Elena Gracheva, University of California, San Francisco, CA) with primers oGH368 and oGH676; the fragment was inserted into the pETduet-1 vector amplified using oGH332 and oGH336 using the Gibson assembly reaction. This places the coding sequence downstream of the first T7 promoter. The C-terminus is tagged with a three amino acid linker (GSS) followed by a hexa histidine-tag (His-tag). The coding sequence of mouse AP2 mu1 (amino acids 1--435, NM_009679) was amplified (oGH370 + oGH371) and inserted downstream of the second T7 promoter (oGH338 + oGH339) using the Gibson reaction. The His-tagged mu domain of AP2 mu1 expression construct is pGH441: This construct was generated by amplifying a portion of pGH424 (oGH571 + oGH921) starting with the linker and mu domain of the mu2 protein, continuing around the plasmid backbone, and ending with the first T7 promoter. This PCR product removed the beta trunk along with the sigma-homology domain of mu while appending a His-tag to the N-terminus of the linker, and was circularized using the Gibson assembly reaction. The His-tagged beta appendage domain expression construct is pGH491: Sequence encoding the C-terminus of mouse AP2 beta 1 (amino acids 592--951) was amplified using oGH1161-2 and recombined with the His-tag, T7 promoter and vector backbone portion of the His-tagged mu domain construct (pGH441 amplified with pGH571 and oGH339) using Gibson assembly. The His-tagged alpha appendage expression construct is pGH492: cDNA corresponding to the linker + appendage domain (amino acids 622--938) of mouse AP2 alpha 2 (NM_007459) was amplified (oGH1163-4) and cloned using the same strategy as the beta appendage expression construct (pGH491, above). The His-tagged HaloTag-APA expression vector is pGH493: The His-tag, T7 promoter and backbone regions of the mu domain construct (pGH441 amplified with pGH853 and oGH1165) was recombined with PCR products corresponding to HaloTag (amplified using oGH1166-7) and the APA domain of mouse SGIP1 (oGH1169 + oGH861) using the Gibson reaction. The control construct to express the His-tagged HaloTag alone in bacteria is pGH494: The HaloTag coding sequence was amplified (oGH1166 + oGH1171) and recombined with the His-tag, T7 promoter and backbone regions of the AP2 mu domain construct (pGH441 amplified with oGH1170 + oGH1165). The vector expressing the trunk domain of mouse AP2 alpha 2 with a C-terminal GST tag along with mouse AP2 sigma 2 ([@bib5]) was a gift from Volker Haucke (FMP, Berlin, Germany). Plasmids and oligonucleotides are listed in [Supplementary files 1B,C](#SD1-data){ref-type="supplementary-material"}, respectively.

Each AP2 hemicomplex was expressed independently. Expression vectors were transformed into Rosetta (DE3)pLysS cells (EMD Millipore, Billerica, MA) and grown overnight at 20°C in LB containing 200 μM IPTG, chloramphenicol (34 μg/ml), and ampicillin (100 μg/ml) for the His-tagged proteins and kanamycin (25 μg/ml) for the alpha/sigma hemicomplex. Cells were collected by centrifugation, washed with distilled water and re-pelleted prior to rapid freezing. Cell pellets were resuspended in lysis buffer (50 mM HEPES, 300 mM NaCl, 10 mM imidazole, pH 7.5) and incubated with 1 mg/ml lysozyme at 4°C prior to sonication and centrifugal clarification. To purify His-tagged proteins, lysates were incubated with Talon cobalt resin (Clontech, Mountain View, CA), washed with lysis buffer containing 20 mM imidazole and eluted with lysis buffer containing 200 mM imidazole. To purify the alpha/sigma hemicomplex, lysate was incubated with glutathione agarose (Pierce, Thermo Fisher Scientific, Rockford, IL) and then washed with lysis buffer prior to eluting with lysis buffer containing 10 mM reduced glutathione. Purified proteins were dialyzed in 25 mM HEPES, 100 mM KCl, pH 7.5 and stored as frozen aliquots at −80°C. For the pulldown assay, 80 pmoles of purified HaloTag ± APA bait were diluted along with 40 pmoles of recombinant AP2 prey and 10 μl of magnetic HaloLink beads (20% slurry) in 1x TBS containing 0.05% IGEPAL CA-630 (1 ml total volume for each pulldown) and nutated overnight at 4°C. Beads were washed with 1× TBS +0.05% IGEPAL CA-630 and bound proteins were cleaved from the HaloTag by incubation with AcTEV protease (30 µl at 50 units/ml for 60 min at 22°C). 50% of this elution was separated by SDS-PAGE and silver-stained along with 25% of the prey input for comparison. AP2 hemicomplexes are soluble under these conditions. To purify AP2 for crystallographic studies it was found that hemicomplexes were insoluble ([@bib5]). Note that the protein concentrations used in our pulldown assay (∼10 μg/ml) are roughly 1000-fold lower than those indicated for the crystallization (∼10 mg/ml).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "FCHo and SGIP proteins are allosteric activators of the AP2 clathrin adaptor complex" for consideration at *eLife.* Your article has been favorably evaluated by Vivek Malhotra (Senior editor) and 3 reviewers, one of whom, Suzanne Pfeffer, is a member of our Board of Reviewing Editors.

This is an elegant study from the Jorgensen lab that demonstrates a role for the endocytic adaptor FCHo in promoting AP-2 function. Taking advantage of *C. elegans* genetics, the authors identify an enormous set of mutations within subunits of the AP-2 complex during an *fcho* mutant suppressor screen. The mutations cluster in a manner that suggests they stabilize an open conformation for the AP-2 complex. Indeed, using an elegant in vivo protease sensitivity assay, several bypass mutants show enhanced cleavage, suggesting that they exist in a more open state. Additional experiments, including a clever second site suppressor analysis, further support this conclusion. The authors also identify a short, conserved sequence in FCHo (the APA domain), which is sufficient to promote AP-2 activity and rescue a subset of phenotypes exhibited by *fcho* mutant animals. In general, the work is rigorous and convincing, finally highlighting the relevance of different conformational states to AP-2 function in vivo. Nonetheless, the following issues should be addressed before publication can be recommended.

1\) The significance of the paper would be enhanced if the authors would map the interaction between the proteins more precisely and provide an estimate of the affinity of the interaction; they should also provide specific information in terms of how the fragment affects AP2 behavior on the membrane.

2\) A predicted AP-2 cargo is shown to accumulate on the surface of intestinal cells when FCHo is absent. However, there a pool of the cargo that continues to accumulate intracellularly in this mutant background. How does the *fcho* mutant phenotype compare to that of a strain that lacks the alpha subunit of AP-2? And in the double mutant lacking both the alpha subunit and *fcho*? The issue here is really trying to distinguish whether FCHo has functions outside of its role as an AP-2 activator. Since none of the bypass mutants could fully suppress the *fcho* deletion, it would suggest that FCHo functions independently of AP-2 as well. Can the authors clarify (either with this intestinal endocytosis assay or otherwise)?

3\) Is there a consequence (with regard to endocytosis) to animals expressing a constitutively active form of AP-2 (e.g., the bypass mutants)? Is endocytosis enhanced in animals that harbor bypass mutations in an otherwise wild type background? If not, can the authors comment on why a transition from a closed to an open state might be beneficial?

4\) In a similar vein, is the mobility/clustering of the alpha subunit altered in animals expressing one of the bypass mutants, as measured by FRAP? One might expect that the constitutively open state may translate into enhanced stabilization at the cell surface. Such a finding would be highly informative and enhance the impact of this study.

5\) Continuing on this line of reasoning, what is the effect of expressing the APA domain on the mobility/clustering of the alpha subunit in coelomocytes?

6\) The rescue of *fcho* mutants by the APA domain alone is somewhat surprising, as it is unclear how this fragment would be appropriately targeted. Perhaps its interaction with AP-2 is sufficiently strong to enable its localization? Unfortunately, there is no evidence to support this possibility at present. Can the authors express the domain (perhaps as a fluorescently tagged protein) and determine whether it accumulates at the cell surface, as one would anticipate? In this way, the authors could also determine which subunit (or at least hemicomplex) of AP-2 is necessary for targeting, as localization studies could be conducted in both alpha and mu deletion backgrounds.

10.7554/eLife.03648.023

Author response

*1) The significance of the paper would be enhanced if the authors would map the interaction between the proteins more precisely and provide an estimate of the affinity of the interaction; they should also provide specific information in terms of how the fragment affects AP2 behavior on the membrane*.

The reviewers suggested that the interaction of the APA domains of FCHo and SGIP with AP2 be further characterized: We determined that the APA domain binds specifically and directly to both hemicomplexes of the AP2 core. We expressed His-tagged or GST-tagged AP2 subunits (or domains) in bacteria, and separately expressed a Halo-tagged SGIP1 APA fragment and purified the recombinant proteins. The Halo-tagged APA fragment was conjugated to beads; the AP2 constructs were affinity-purified on these beads and identified on silver-stained gels. These data are included in [Figure 7C](#fig7){ref-type="fig"}.

Results section: "We demonstrated that the interaction between the APA domain and the AP2 core is direct using purified recombinant proteins in pulldown assays ([Figure 7C](#fig7){ref-type="fig"}). The APA domain does not appear to bind the appendages of the large adaptins, nor to the mu domain alone. Rather, it bridges the complex since the APA bait binds both the alpha/sigma and beta/mu hemicomplexes."

Discussion section: "... we find that the interior of the linker binds the core complex."

We attempted to determine the affinity of the APA domain for the AP2 core using Fluorescent Correlation Spectroscopy. We labeled the purified HaloTag proteins with the fluorescent ligand TMR and incubated with increasing concentrations of the purified AP2 core complex. We repeated these experiments three times but the results were not significant. This is partly due to the fact that when the fluorescent Halo-tagged APA binds to the AP2 core, the shift in diffusion rate is not large enough to consistently rise above the baseline nor the diffusion rate of our negative control (purified HaloTag lacking the APA). We do see a deflection in the diffusion rate of the fluorescent APA domain when the concentration of AP2 core approaches 1 μM, however we are not convinced and do not feel comfortable publishing these data.

When overexpressed in *fcho-1* mutants, the APA domain alone is sufficient to increase AP2 association with the membrane as assayed by FRAP. Moreover, the APA fragment can organize the complex into puncta on the coelomocyte membrane and is thus likely assembling into presumptive endocytic pits. These data are shown in [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}.

In the text: "Expression of this short fragment alone was capable of rescuing *fcho-1* mutants, including growth rate, and endocytosis of cargo ([Figure 6C](#fig6){ref-type="fig"} and [Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"}). This fragment is also sufficient to immobilize AP2 on the membrane in the photobleaching assay and to cluster AP2 into presumptive endocytic pits ([Figure 6--figure supplement 1](#fig6s1){ref-type="fig"})."

*2) A predicted AP-2 cargo is shown to accumulate on the surface of intestinal cells when FCHo is absent. However, there a pool of the cargo that continues to accumulate intracellularly in this mutant background. How does the* fcho *mutant phenotype compare to that of a strain that lacks the alpha subunit of AP-2? And in the double mutant lacking both the alpha subunit and* fcho*? The issue here is really trying to distinguish whether FCHo has functions outside of its role as an AP-2 activator. Since none of the bypass mutants could fully suppress the* fcho *deletion, it would suggest that FCHo functions independently of AP-2 as well. Can the authors clarify (either with this intestinal endocytosis assay or otherwise)?*

The reviewers are asking whether FCHo has functions beyond activation of AP2. We have now tested this by assays in double knockouts in the pathway, in *fcho-1* mutants expressing just the APA fragment, and in *fcho-1* null mutants with suppressors (as described below). Although we lack data demonstrating other roles for FCHo, we think that it is quite likely given the conservation of the mu homology domain and its known interactions. We describe these new data in the Results and now acknowledge that FCHo is likely to have other roles in the Discussion.

The first and best method of testing for other roles is to assay for enhanced phenotypes in mutants lacking both FCHo and AP2. We found that surface retention of the artificial cargo was not enhanced in the double mutants lacking *fcho-1* and each of the AP2 subunits alpha, sigma, or mu.

In the text: "However, this cargo accumulates on the cell surface in both AP2 and *fcho-1* mutants, suggesting that AP2-dependent endocytosis is defective in *fcho-1* mutants ([Figure 1--figure supplement 1D](#fig1s1){ref-type="fig"}). In addition the phenotype is not enhanced in double mutants indicating that FCHO-1 acts in the same pathway as AP2."

The second method is to assay *fcho-1* nulls expressing the APA activating fragment. The APA fragment almost fully rescues *fcho-1* phenotypes for morphology, growth and endocytosis.

In the text: "Expression of this short fragment alone was capable of rescuing *fcho-1* mutants, including growth rate, endocytosis of cargo, and morphology ([Figure 6C](#fig6){ref-type="fig"}, [Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"} and not shown)."

The third method is to assay *fcho-1* nulls with suppressor mutations. The activated AP2 mutations that result in the most open (protease sensitive) and phosphorylated AP2 complex fully rescue the morphological and growth defects of the *fcho-1* deletion ([Figure 4A](#fig4){ref-type="fig"}).

Nevertheless, these mutations do not fully restore clearance of an artificial cargo from the surface of the intestine. There are two possible reasons: either the activated AP2 mutations cannot recapitulate all of the normal functions of the AP2 complex, or there are other functions of FCHo beyond its actions on AP2.

In the text: "However, none of these mutations fully restored cargo endocytosis, even though all of the suppressors rescued growth and morphology ([Figure 4A](#fig4){ref-type="fig"} and not shown). Only the mutation that resulted in a profoundly protease-hypersensitive complex (μE306K) increased cargo internalization with high significance in *fcho-1* mutants. These findings indicate that subtle conformational changes favoring active AP2 satisfied an organismal requirement for FCHO-1 without fully compensating for the endocytic defect of *fcho-1* mutants."

Discussion section: "The activated AP2 mutations that result in the most open (protease sensitive) and phosphorylated AP2 complex fully rescue the morphological and growth defects of the *fcho-1* deletion. Nevertheless, these mutations do not fully suppress clearance of an artificial cargo from the surface of the intestine. It is likely that the activated AP2 mutations cannot recapitulate all of the normal functions of the AP2 complex, and that FCHo has other functions beyond its actions on AP2, for example via interactions with Eps15 or Disabled-2 ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"} and [1C](#fig7s1){ref-type="fig"}) ([@bib16]; [@bib26]; [@bib27]; [@bib35]; [@bib43]; [@bib44])."

3\) Is there a consequence (with regard to endocytosis) to animals expressing a constitutively active form of AP-2 (e.g., the bypass mutants)? Is endocytosis enhanced in animals that harbor bypass mutations in an otherwise wild type background? If not, can the authors comment on why a transition from a closed to an open state might be beneficial?

The reviewers are asking whether open AP2 mutants exhibit enhanced endocytosis in the intestine. We performed the cargo assay in five strains bearing activated mu2 mutations in an otherwise wild-type background ([Figure 8A](#fig8){ref-type="fig"}). None of these mutants internalize more of the artificial cargo than the wild type. We have not observed an overt phenotype associated with constitutively open AP2 other than their ability to bypass the requirement for FCHo/SGIP proteins.

In the text: "Nor do these mutants exhibit enhanced endocytosis or membrane association in an otherwise wild-type background ([Figure 8](#fig8){ref-type="fig"}). It is possible that compensatory mechanisms counteract the open state of these AP2 mutants."

Why is a transition from a closed to open state likely to be beneficial? The existence of a closed, soluble form of AP2 is probably important for trafficking the complex from recently formed vesicles back to the plasma membrane to initiate new sites of endocytosis. The open form is configured to bind membrane and cargo simultaneously, and the change in conformation in the superstructure probably signals the recruitment of clathrin.

If the constitutively activated forms cannot adopt the closed state, why don't they affect endocytic trafficking? A complex that is in the open state could both enhance and slow cycling of the complex and may therefore superficially resemble the wild type, or the opening of AP2 may not be rate-limiting, or additional mechanisms may prevent AP2 hyperactivity.

In the text: "How then does FCHo promote the AP2 cycle? The formation of a closed form of AP2 is probably required to unbind membranes from newly endocytosed vesicles and to scan the membrane for new sites of endocytosis. The coincidental presence of FCHo, cargo, and PIP2 can then stabilize the open state, and the conformational changes in the complex then nucleate recruitment of clathrin and other pit components ([Figure 4--figure supplement 1A](#fig4s1){ref-type="fig"}; [@bib20])."

*4) In a similar vein, is the mobility/clustering of the alpha subunit altered in animals expressing one of the bypass mutants, as measured by FRAP? One might expect that the constitutively open state may translate into enhanced stabilization at the cell surface. Such a finding would be highly informative and enhance the impact of this study*.

The activating mutations do not appear to significantly stabilize or cluster the AP2 complex on the cell surface beyond levels exhibited by the wild-type AP2 complex. We analyzed the same five bypass mutants evaluated in the cargo assay above using FRAP to monitor the mobility of AP2 ([Figure 8B](#fig8){ref-type="fig"}) and variance analysis to quantify the clustering of AP2 ([Figure 8C](#fig8){ref-type="fig"}). None were significantly better than the wild-type AP2 complex. Again, it is possible that constitutively open AP2 elicits compensatory mechanisms or that the mutations are not so severe as to lead to a constitutively adherent complex.

Same quote as for point 3: "Nor do these mutants exhibit enhanced endocytosis or membrane association in an otherwise wild-type background ([Figure 8](#fig8){ref-type="fig"}). It is possible that compensatory mechanisms counteract the open state of these AP2 mutants."

5\) Continuing on this line of reasoning, what is the effect of expressing the APA domain on the mobility/clustering of the alpha subunit in coelomocytes?

Overexpression of the APA domain rescues the mobility and the clustering of the alpha subunit in coelomocytes (see [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}).

In the text: "Expression of this short fragment alone was capable of rescuing *fcho-1* mutants, including growth rate, endocytosis of cargo, and morphology ([Figure 6C](#fig6){ref-type="fig"}, [Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"}, and not shown). This fragment is also sufficient to immobilize AP2 on the membrane in the photobleaching assay and to cluster AP2 into presumptive endocytic pits ([Figure 6--figure supplement 1](#fig6s1){ref-type="fig"})."

*6) The rescue of* fcho *mutants by the APA domain alone is somewhat surprising, as it is unclear how this fragment would be appropriately targeted. Perhaps its interaction with AP-2 is sufficiently strong to enable its localization? Unfortunately, there is no evidence to support this possibility at present. Can the authors express the domain (perhaps as a fluorescently tagged protein) and determine whether it accumulates at the cell surface, as one would anticipate? In this way, the authors could also determine which subunit (or at least hemicomplex) of AP-2 is necessary for targeting, as localization studies could be conducted in both alpha and mu deletion backgrounds*.

All of the structure-function FCHO-1 constructs, and mammalian FCHo and SGIP constructs were tagged at the N-terminus with TagRFP-T ([Figure 6B and C](#fig6){ref-type="fig"}). We examined the localization of the APA domain from mouse SGIP in coelomocytes ([Figure 7--figure supplement 1D](#fig7s1){ref-type="fig"}). The RFP-APA accumulates on the cell surface and overlaps with the GFP-tagged AP2 alpha subunit. In the absence of the mu subunit, the APA fragment is no longer enriched on the cell surface, even though the AP2 alpha-GFP retains the ability to localize to the plasma membrane (although not in a productive manner). This result demonstrates that the AP2 holocomplex is required to generate the APA binding site and is consistent with our *in vitro* biochemistry.

In the text: "The interaction of the APA domain with AP2 likely occurs *in vivo* as well, since fluorescently tagged APA colocalizes with AP2 on the membrane in coelomocytes, and membrane association is lost in mutants lacking the mu2 subunit ([Figure 7--figure supplement 1D](#fig7s1){ref-type="fig"})."

[^1]: Department of Biochemistry, University of Utah, Salt Lake City, United States.

[^2]: Department of Biochemistry, University of Washington, Seattle, United States.
